CoChat

Pharmacological inhibition of the transcription factor PU.1 in leukemia

Open access

The DOI matches its Crossref record; 56 of the 58 references it cites were found in a registry or an index.

Abstract

The transcription factor PU.1 is often impaired in patients with acute myeloid leukemia (AML). Here, we used AML cells that already had low PU.1 levels and further inhibited PU.1 using either RNA interference or, to our knowledge, first-in-class small-molecule inhibitors of PU.1 that we developed specifically to allosterically interfere with PU.1-chromatin binding through interaction with the DNA minor groove that flanks PU.1-binding motifs. These small molecules of the heterocyclic diamidine family disrupted the interaction of PU.1 with target gene promoters and led to downregulation of canonical PU.1 transcriptional targets. shRNA or small-molecule inhibition of PU.1 in AML cells from either PU.1lo mutant mice or human patients with AML-inhibited cell growth and clonogenicity and induced apoptosis. In murine and human AML (xeno)transplantation models, treatment with our PU.1 inhibitors decreased tumor burden and resulted in increased survival. Thus, our study provides proof of concept that PU.1 inhibition has potential as a therapeutic strategy for the treatment of AML and for the development of small-molecule inhibitors of PU.1.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci92504

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 56 references

Research works printed but not linked: 1

  1. Nanjunda RM, Munde M, Liu M, Wilson WD. Real-time monitoring of nucleic acid interactions with biosensor surface plasmon resonance. In: Wanunu Y, ed. Methods for Studying DNA/ Drug Interactions. Boca Raton, FL: CRC Press; 2011:92-122.

Cited by

Metadata

Authors
Antony-Debré, I., Paul, A., Leite, J., Mitchell, K., Kim, H. M., Carvajal, L. A., Todorova, T. I., Huang, K., Kumar, A., Farahat, A. A., Bartholdy, B., Narayanagari, S.-R., Chen, J., Ambesi-Impiombato, A., Ferrando, A. A., Mantzaris, I., Gavathiotis, E., Verma, A., Will, B., Boykin, D. W., Wilson, W. D., Poon, G. M. K., & Steidl, U.
Affiliations
  • Georgia State University (US)
  • Albert Einstein College of Medicine (US)
  • Mansoura University (EG)
  • Columbia University (US)
Corresponding author
Steidl, Ulrich
Venue
Journal of Clinical Investigation
Published
2017-10-30
Volume
127
Issue
12
Pages
4297-4313
ISSN
  • 0021-9738 (ISSN-L)
  • 1558-8238
OpenAlex
W2766367793
Cited by
120
References
58
Citations by year
2026: 7 · 2025: 12 · 2024: 10 · 2023: 16 · 2022: 19 · 2021: 11 · 2020: 15 · 2019: 17 · 2018: 11 · 2017: 2
FWCI
9.48
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, other-oa)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • Leukemia & Lymphoma Society (6504-17)
  • Henry and Marilyn Taub Foundation (Taub Foundation Grants Program for MDS Research)
  • National Institutes of Health (R01CA217092)
Topics
  • Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
Keywords
PU.1, acute myeloid leukemia, transcription factor inhibition, small molecule inhibitors, allosteric inhibition, DNA minor groove, chromatin binding, RNA interference, apoptosis, therapeutic target
MeSH terms
THP-1 Cells, Proto-Oncogene Protein Spi-1, Allosteric Regulation, Animals, Chromatin, Humans, Mice, Transgenic, Pentamidine, Proto-Oncogene Proteins, Leukemia, Myeloid, Acute, Trans-Activators, Apoptosis, Xenograft Model Antitumor Assays, RNA Interference, Mice, HEK293 Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.